scholarly article | Q13442814 |
P2093 | author name string | Bing Li | |
Xi-Xu Zhu | |||
Xin-Hu Wu | |||
Ze-Tian Shen | |||
P2860 | cites work | Accuracy of tumor motion compensation algorithm from a robotic respiratory tracking system: a simulation study. | Q50735226 |
Prognosis and survival in resected lung carcinoma based on the new international staging system | Q69835930 | ||
Radiation therapy alone for stage I non-small cell lung cancer | Q72569985 | ||
Evaluation of microscopic tumor extension in non-small-cell lung cancer for three-dimensional conformal radiotherapy planning | Q73174029 | ||
[Feasibility and efficacy of cyberknife radiotherapy for lung cancer: early results] | Q81790688 | ||
Treatment of early non-small cell lung cancer, stage IA, by image-guided robotic stereotactic radioablation--CyberKnife | Q95779507 | ||
New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1) | Q28131668 | ||
Stereotactic radiotherapy with real-time tumor tracking for non-small cell lung cancer: clinical outcome | Q33419548 | ||
Stereotactic body radiation therapy for inoperable early stage lung cancer | Q34010065 | ||
Excessive toxicity when treating central tumors in a phase II study of stereotactic body radiation therapy for medically inoperable early-stage lung cancer | Q34575077 | ||
Randomized trial of lobectomy versus limited resection for T1 N0 non-small cell lung cancer. Lung Cancer Study Group | Q34721402 | ||
Radical stereotactic radiosurgery with real-time tumor motion tracking in the treatment of small peripheral lung tumors | Q36326883 | ||
Cancer as a manifestation of aberrant chromatin structure | Q36651427 | ||
Robotic whole body stereotactic radiosurgery: clinical advantages of the Cyberknife integrated system | Q36828679 | ||
CyberKnife radiosurgery for stage I lung cancer: results at 36 months | Q36965063 | ||
Patterns of disease recurrence after stereotactic ablative radiotherapy for early stage non-small-cell lung cancer: a retrospective analysis | Q38021143 | ||
Radiotherapy alone for medically inoperable stage I non-small-cell lung cancer: the Duke experience | Q41677591 | ||
Measurements of the relative output factors for CyberKnife collimators | Q46085024 | ||
Stereotactic radiosurgery for lung tumors: preliminary report of a phase I trial | Q46254774 | ||
Extracranial stereotactic radioablation: results of a phase I study in medically inoperable stage I non-small cell lung cancer | Q48151239 | ||
Early results of CyberKnife image-guided robotic stereotactic radiosurgery for treatment of lung tumors | Q48898583 | ||
P275 | copyright license | Creative Commons Attribution 4.0 International | Q20007257 |
P6216 | copyright status | copyrighted | Q50423863 |
P433 | issue | 3 | |
P304 | page(s) | 55 | |
P577 | publication date | 2015-02-01 | |
P1433 | published in | Medical Oncology | Q2152666 |
P1476 | title | Clinical outcomes of CyberKnife stereotactic body radiotherapy for peripheral stage I non-small cell lung cancer | |
P478 | volume | 32 |
Q47877896 | A phase I/II study on stereotactic body radiotherapy with real-time tumor tracking using CyberKnife based on the Monte Carlo algorithm for lung tumors |
Q38663392 | Clinical Outcomes of 130 Patients with Primary and Secondary Lung Tumors treated with Cyberknife Robotic Stereotactic Body Radiotherapy |
Q37691881 | Clinical outcomes of CyberKnife stereotactic radiosurgery for elderly patients with presumed primary stage I lung cancer |
Q37109928 | Comparing the clinical outcomes in stereotactic body radiotherapy for lung tumors between Ray-Tracing and Monte-Carlo algorithms |
Q36382039 | Comparison of particle beam therapy and stereotactic body radiotherapy for early stage non-small cell lung cancer: A systematic review and hypothesis-generating meta-analysis |
Q40496623 | Dosimetric factors predicting radiation pneumonitis after CyberKnife stereotactic body radiotherapy for peripheral lung cancer |
Q58584561 | Treatment-Related Adverse Effects in Lung Cancer Patients after Stereotactic Ablative Radiation Therapy |
Search more.